Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Insider Sells 709 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 709 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $28,310.37. Following the transaction, the insider now owns 78,996 shares of the company’s stock, valued at $3,154,310.28. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Dennis Cho also recently made the following trade(s):

• On Tuesday, July 2nd, Dennis Cho sold 126 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $6,048.00.
• On Thursday, June 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The stock was sold at an average price of $49.41, for a total transaction of $11,561.94.
• On Friday, June 14th, Dennis Cho sold 95 shares of Twist Bioscience stock. The shares were sold at an average price of $51.04, for a total transaction of $4,848.80.
• On Thursday, June 6th, Dennis Cho sold 276 shares of Twist Bioscience stock. The shares were sold at an average price of $51.33, for a total value of $14,167.08.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded down $1.64 on Wednesday, reaching $44.60. The company’s stock had a trading volume of 1,109,494 shares, compared to its average volume of 1,052,113. The company has a 50-day simple moving average of $50.72 and a 200 day simple moving average of $41.58. The company has a market cap of $2.60 billion, a P/E ratio of -13.27 and a beta of 1.80. Twist Bioscience Co. has a 52-week low of $14.42 and a 52-week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The company had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The company’s revenue was up 27.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.01) earnings per share. On average, equities research analysts forecast that Twist Bioscience Co. will post -3.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on TWST shares. Barclays cut their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday. The Goldman Sachs Group boosted their target price on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. TD Cowen raised their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Guggenheim began coverage on shares of Twist Bioscience in a research note on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price target on the stock. Finally, Evercore ISI increased their price objective on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.22.

Institutional Trading of Twist Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. International Assets Investment Management LLC increased its position in Twist Bioscience by 3,519.8% during the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock valued at $148,000 after acquiring an additional 3,907 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Twist Bioscience by 2.9% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock worth $132,086,000 after purchasing an additional 99,511 shares during the period. Knights of Columbus Asset Advisors LLC bought a new position in Twist Bioscience during the 4th quarter valued at about $2,296,000. New York State Common Retirement Fund raised its position in Twist Bioscience by 5.0% in the 4th quarter. New York State Common Retirement Fund now owns 370,849 shares of the company’s stock worth $13,669,000 after purchasing an additional 17,715 shares during the period. Finally, Victory Capital Management Inc. bought a new stake in Twist Bioscience in the fourth quarter worth about $274,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.